Acthar® Gel (repository corticotropin injection) Reference Bibliography

This bibliography contains verifiable peer-reviewed manuscripts and abstracts on the use of Acthar Gel, as well as publications supported by Mallinckrodt that relate to Acthar directly or indirectly. Human and preclinical studies, health economic and outcomes analyses (HEOR), reports and reviews are included and, where available, links to PubMed are provided.

Updated: August 2020

Nephrology


### Nephrology


### Neurology


99. Chugani HT, Kumar A. Neuroinflammation in children with infantile spasms: a prospective study before and after treatment with Acthar Gel (Repository Corticotropin Injection). *J Child Neurol.* 2020;[published online: June 23, 2020] [Link](#)


108. Goldstick L, Miller A, Due B, Bauer W, Zhao E, Cohen J, Robertson D, Wynn D. Study design of the randomized, double-blind, placebo-controlled options study of repository corticotropin


144. Pauli L, O'Neil R, Ybanez M, Livingston S. Minor motor epilepsy. Treatment with corticotropin (ACTH) and steroid therapy. JAMA. 1960;174:1408-1412. Link


Neurology – HEOR


Ophthalmology


208. Chen E, Reynolds H, Graham L. Ocular cicatricial pemphigoid treated with intramuscular corticotropin injections. JAAD Case Reports. 2020;6(5):450-452. Link


Ophthalmology HEOR


**Pulmonology**


**Pulmonology – HEOR**


**Rheumatology**


256. Decker D, Furie R, Li D, Mathura E, Becker PM. Plasma Soluble Vascular Adhesion Molecule-1 (sVCAM-1) as an exploratory marker of response to therapy in patients with


271. Fleischmann R, Furst DE, Brasington R, Connolly-Strong E, Liu J, Barton ME. A multicenter study assessing the efficacy and safety of repository corticotropin injection in patients with


Pegram SB. The efficacy and tolerability of H.P. Acthar® Gel (repository corticotropin injection) for the treatment of systemic lupus erythematosus [EULAR abstract AB0531]. *Ann Rheum Dis.* 2015;74(suppl 2):1077-1078


Wu A, June J. Case series: Comparison of repository corticotropin injection (H.P. Acthar Gel) versus glucocorticoids on bone density in SLE patients [ACR abstract 331]. *Arthritis Rheumatol.* 2017;69(supp 10): 452

Zutshi DW, Friedman M, Ansell BM. Corticotrophin therapy in juvenile chronic polyarthritis (still's disease) and effect on growth. *Arch Dis Child.* 1971;46(249):584-593. [Link]


**Other**


335. Baram TZ. What are the reasons for the strikingly different approaches to the use of ACTH in infants with West Syndrome? *Brain and Development.* 2001;7:647-648. [Link](#)


370. Decker D, Higgins P, Bendele A, Becker P. Repository corticotropin injection (H.P. Acthar® Gel) attenuates established collagen-induced arthritis when used alone or as adjuvant therapy with Etanercept (Enbrel®) [AAI abstract THER5P.902]. *J Immunol.* 2015;194(suppl 1):139.4-139.4


23


408. Lisak R, Nedelkoska L, Benjamins J. ACTH1-39 protection of oligodendrocytes from damage relevant to multiple sclerosis involves both direct and indirect mechanisms. [AAN abstract P2.189]. *Neurology.* 2015;84(suppl 14):P2.189


411. Lisak R, Nedelkoska L, Touil H, Bar-Or A, Benjamins J. Sigma 1 receptor and melanocortin receptor agonists protect oligodendroglia from death induced by products of B cells from multiple sclerosis patients. [ECTRIMS abstract P582]. *Mult Scler.* 2018;24(S2):280


422. Montroy T, Fiechtner JJ. A single-site, investigator initiated, open-label trial of the adrenocorticotropic hormone (ACTH) analogue HP Acthar Gel (repository corticotropin
injection) among subjects with moderately to severely active systemic lupus erythematosus (SLE) [EULAR abstract AB0382]. Ann Rheum Dis. 2013;72(suppl 3):904


Obi O, Judson M, Maier L, Wells A, Baughman R. Role of baseline dyspnea index (BDI) and transition dyspnea index (TDI) as a measure of self-reported health related quality of life in sarcoidosis patients [ATS abstract A5609]. Am J Respir Crit Care Med. 2019;199:A5609.


There is a vast body of clinical data in the peer-reviewed literature regarding the therapeutic use of Acthar® Gel (repository corticotropin injection). For more information, please contact our Medical Information Group by phone at 800.844.2830, by fax at 913.451.6409, or by email at medinfo@mnk.com